CANbridge Life Sciences Submits Investigational New Drug Application for CAN017 Trial in Esophageal Squamous Cell Cancer (ESCC) in China

CANbridge Completes Patient Enrolment for Phase I Clinical Trial of CAN008 in Treatment of Glioblastoma Multiforme in Taiwan

CAN008 Injection for the Treatment of Gbm China Taiwan Phase I Data Releasing

James Xue is Appointed to Leadership and Development Council Member

CANbridge Life Sciences Appoints Chief Business Officer Will Head First US Office

CANbridge Congratulates Apogenix APG101 Receiving Ema “Prime” Designation

CANbridge Submits Ind Application for CAN008 PHII/III Trial in GBM in China

James Xue, Founder and CEO of CANbridge, Present at 2017 China GCP Conference

James Xue, Founder and CEO of CANbridge, Present at 2017 Boston CEO Conference